In May 2014 Giuseppe joined the IIT TTO group, after almost a couple of years within the IIT Drug Discovery & Development (D3) Unit. Key activities in his current role are:
- Market analysis of IIT technologies within the Life Sciences/Pharma sector; branding the most advanced and mature projects within the scientific & business communities to identify and exploit potential partnership and licensing opportunities for IIT Pharma patent applications & assets; matching internal research projects/compounds with market demand and funding opportunities within the investors’ community.
- Management of IIT patent portfolio in the Pharma sector, by revising the record of inventions coming from scientists, managing technical relationships with external patent attorneys, drafting/reviewing patent applications prior to filing, and defining foreign filing and nationalization strategies based on projects/compounds preclinical development status and licensing opportunities.
Giuseppe spent 30 years in the drug discovery arena of life sciences, being involved in all the relevant aspects of the drug discovery & preclinical development process, from synthetic & medicinal chemistry, biochemical pharmacology and ADMET/DMPK profiling of emerging leads to candidate selection and advanced preclinical development studies.
He managed resources up to 90 people (Zambeletti-Beecham, SmithKline Beecham, GlaxoSmithKline and NiKem Research) and was exposed to various aspects of the value chain in the big pharma & CRO outsourcing industries in a variety of top management roles: science, finance, administration, business development, marketing, institutional & public relations. His main expertise is in medicinal chemistry, patenting strategies and portfolio management of small molecule therapeutics, preclinical profiling up to candidate selection and business development of mature projects through licensing or spin-off deals.
During the last 15 years Giuseppe developed excellent negotiations skills within Business Development & Licensing areas, greatly contributing to bring to success the following main deals:
He has a strong interest in teaching and training, and delivered hundreds of hours of seminars to students and professionals at several academic institutions and industrial locations.
He is a member of the Editorial Board of “Pharmaceutical Patent Analyst” (Future Science Group), co-inventor of 37 patent families and author of more than 100 presented works (54 scientific papers on peer-reviewed journals, 26 invited lectures/seminars to congresses and workshops, and 22 poster presentations).
The antitussive activity of delta opioid receptor stimulation in guinea pigs. C.J. Kotzer, D.W.P. Hay, M. Dondio, G.A.M. Giardina, P. Petrillo, and D. Underwood. J. Pharmacol. Exp. Ther., 2000 292, 803-809.
The opioid- receptor-like 1 (ORL-1) as a potential target for new analgesics. D. Barlocco, G. Cignarella, G.A.M. Giardina and L. Toma. Eur. J. Med. Chem., 2000, 35, 275-282.
Recent advances on Neurokinin-3 (NK-3) receptor antagonists. G.A.M. Giardina, L. Raveglia and M. Grugni. Exp. Opin. Ther. Pat., 2000, 10(6), 939-960.
Moderni Criteri di Sviluppabilità del Farmaco. G.A.M. Giardina. Cronache Farmaceutiche, 2000, 2, 75-78.
Evidence that the proposed novel human “Neurokinin-4” receptor is pharmacologically similar to the human Neurokinin-3 receptor but is not of human origin. H.M. Sarau, J.L. Mooney, D.B. Schmidt, J.J. Foley, P.T. Buckley, G.A.M. Giardina, D.Y. Wang, J.A. Lee, D.W.P. Hay. Molecular Pharmacol., 2000, 58, 552-559.
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and Pharmacokinetic profile of SB 222200, a CNS-penetrant, potent and selective NK-3 receptor antagonist. H.M. Sarau, D.E. Griswold, B. Bush, W. Potts, P. Sandhu, J.J. Foley, D.B. Schmidt, E.F. Webb, L.D. Martin, J.J. Legos, R.G. Whitmore, F.C. Barone, A.D. Medhurst,M.A. Luttmann, G.A.M. Giardina and D.W.P. Hay. J. Pharmacol. Exp. Ther., 2000, 295, 373-381.
La Chimica combinatoria nel processo di drug discovery. G.A.M. Giardina. Atti del Primo Laboratorio della SCI di Metodologie Sintetiche in Chimica Farmaceutica, Siena, Novembre 2001.
Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. G.A.M. Giardina, S. Ronzoni and I. Peretto. Exp. Opin. Ther. Pat., 2001, 11(4), 525-456.
Molecular and pharmacological characterization of the murine tachykinin NK-3 receptor. H.M. Sarau, J.A Field, R.S. Ames, J.J. Foley, P. Nuthulaganti, D.B. Schmidt, P.T. Buckley, N.A. Elshourbagy, M.E. Brawner, M.A. Luttmann, G.A.M. Giardina and D.W.P. Hay. Eur. J. Pharmacol. 2001, 413, 143-150.
Selective Delta Opioid Receptor Agonists for Inflammatory and Neuropathic Pain. G. Dondio, S. Ronzoni, C. Farina, P. Petrillo, C. Manzoni, O. Angelici, G. Petrone, O. Pozzi, P. Zaratin, S. Bingham, M. A. Scheideler and G.A.M. Giardina. IL FARMACO, 2001, 56, 117-119.
Stepwise modulation of NK-3 and NK-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. F. Blaney,L.F. Raveglia, M. Artico, S. Cavagnera, C. Dartois, C. Farina, M. Grugni, S. Gagliardi, M.A. Luttmann, M. Martinelli, G.M.M.G. Nadler, C. Parini, P. Petrillo, H.M. Sarau, M.A. Scheideler, D.W.P. Hay and G.A.M. Giardina. J. Med. Chem., 2001, 44(11), 1675-1689.
A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one (J-113397), the first non-peptide ORL-1 receptor antagonist. C. De Risi,G.P. Pollini, C. Trapella, I. Peretto, S. Ronzoni and G.A.M. Giardina. Bioorg. & Med. Chem., 2001, 9, 1871-1877.
Industrie Chimiche in Italia: La “custom lead optimisation” arriva in Italia. G.A.M. Giardina. La Chimica e L’Industria, 2001, 83, 77-79.
Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low CNS-penetrant, potent and selective NK-3 receptor antagonist, inhibits citric-acid-induced cough and airways hyperreactivity in guinea pigs. D.W.P. Hay, G.A.M. Giardina, D.E. Griswold, D. Underwood, C. Kotzer, B. Bush, W. Potts, P. Sandhu, D. Lundberg, J.J. Foley, D.B. Schmidt, L.D. Martin, D. Kilian, J.J. Legos, F.C. Barone, M.A. Luttmann, M. Grugni, L. Raveglia and H.M. Sarau. J. Pharmacol. Exp. Ther., 2002, 300, 314-323.
Dall’outsourcing della R&S: Le nuove opportunità di business nel settore farmaceutico. G.A.M. Giardina. Economia & Management, 2002, 4, 52.
Morphinan derivatives - A review of the recent patent literature. S. Gagliardi, G. Dondio and G.A.M. Giardina. IDrugs, 2003, 6(2), 129-137.
Antagonists at the neurokinin receptors - Recent patent literature. G.A.M. Giardina, S. Gagliardi and M. Martinelli. IDrugs, 2003, 6(8), 758-772.
Innovazioni nei processi di ricerca in campo farmaceutico. M. Muffatto e G.A.M. Giardina. Economia & Management, 2003, 6, 107-121.
Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).P.F. Zaratin, G. Petrone, M. Sbacchi, M. Garnier, C. Fossati, P. Petrillo, S. Ronzoni, G.A.M. Giardina, and M.A. Scheideler. J. Pharmacol. Exp. Ther., 2004, 308, 454-461.
Microwave-assisted highthroughput chemistry in lead generation and optimization. G.A.M. Giardina, M. Martinelli, A. Mortoni, N. Regalia and S. Gagliardi. Eds. P. Ettmayer, G. Ecker; Joint Meeting on Medicinal Chemistry, Proceedings Wien, June 20th-23rd 2005, pag. 117-122 - Publisher Monduzzi Editore, Bologna, Italy.
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1). Peretto, R. Forlani,C. Fossati, G.A.M. Giardina,A. Giardini, M. Guala, E. La Porta, P. Petrillo, S. Radaelli, L. Radice, L.F. Raveglia, E. Santoro, R. Scudellaro, F. Scarpitta, C. Bigogno, P. Misiano, G.M. Dondio, A. Rizzi, E. Armani, G. Amari, M. Civelli, G. Villetti, R. Patacchini, M. Bergamaschi, M. Delcanale, C. Salcedo, A.G. Fernández and B.P. Imbimbo. J. Med. Chem., 2007, 50, 1571-1583.
Discovery of Diaryl Imidazolidin-2-one Derivatives, a Novel Class of Muscarinic M3 Selective Antagonists (Part 2). Peretto,C. Fossati, G.A.M. Giardina, A. Giardini M. Guala, E. La Porta, P. Petrillo, S. Radaelli, L. Radice, L.F. Raveglia, E. Santoro, R. Scudellaro, F. Scarpitta, A. Cerri, S. Menegon, G.M. Dondio, A. Rizzi, E. Armani, G. Amari, M. Civelli, G. Villetti, R. Patacchini, M. Bergamaschi, Franco Bassani, M. Delcanale and B.P. Imbimbo. J. Med. Chem., 2007, 50, 1693-1697.
Creating effective medicinal chemistry collaborations in drug discovery. G.A.M. Giardina, L.F. Raveglia. Future Med. Chem., 2009, 1(1), 3-6.
Accelerating the Drug Discovery Process: New Tools and Technologies Available to Medicinal Chemists. L.F. Raveglia, G.A.M. Giardina. Future Med. Chem., 2009, 1(6), 1019-1023.
γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer’s Disease: Disappointments and Hopes. B.P Imbimbo and G.A.M. Giardina. Commemorative annual issue, Editor: Allen.B. Reitz. Curr. Topics Med. Chem., 2011, 11(12), 1555-1570.
Ask the experts: IP issues facing researchers. Interview by Pharmaceutical Patent Analyst. , O. Almarsson, M. Angiolini, J. Baell, G. Giardina, A. Ingham, A. Hughes, P. Pevarello, R. Sindelar. Pharmaceutical Patent Analyst, 2012, 1(2), 129-135.